申请人:Surroca Artus Juan Jose
公开号:US20060142376A1
公开(公告)日:2006-06-29
A process for obtaining the pharmaceutical active ingredient, levetiracetam, by means of deaminomethylation of a sufficiently pure enantiomer intermediate (S)-(II), or by means of deaminomethylation of an addition salt thereof with an acid, wherein R
1
and R
2
are either the same or different (C
1
-C
6
)-alkyl radicals, or else R
1
and R
2
together with the nitrogen atom to which they are bonded form a radical selected from the group consisting of 1-pyrrolidinyl, 1-piperidinyl, 1-morpholinyl, 1-piperazinyl and 1-[4-(C
1
-C
4
)-alkylpiperazinyl]. The invention also comprises preparing the sufficiently pure enantiomer intermediate (S)-(II) by treating the corresponding chemically new racemic intermediate (II) with an amine resolving agent, followed by selective crystallisation of a diastereoisomeric salt thereof. It is useful for obtaining levetiracetam on an industrial scale and involves neither hydrogenation nor chromatography.
一种制备药用活性成分左乙拉西坦的方法,通过对足够纯的对映体中间体(S)-(II)进行脱氨甲基化,或者通过将其与酸形成的加合物进行脱氨甲基化,其中R1和R2可以是相同或不同的(C1-C6)烷基基团,或者R1和R2与它们所结合的氮原子一起形成选择自1-吡咯啉基、1-哌啶基、1-吗啉基、1-哌嗪基和1-[4-(C1-C4)-烷基哌嗪基]的基团。该发明还包括通过使用胺分离剂处理相应的化学新的外消旋中间体(II),然后选择性结晶其二对映异构体盐制备足够纯的对映体中间体(S)-(II)。该方法在工业规模上用于制备左乙拉西坦,既不涉及氢化也不涉及色谱法。